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In recent weeks, several new strains of SARS-CoV-2, the 
causative agent of COVID-19, have emerged. These variants 
have evolved an increased transmission rate compared to the 
original strains, which makes controlling this virus even 
more challenging. What has happened, and how do we 
best respond now?
One strain – UK B.1.1.7 lineage (variant of concern 
202012/1) in particular is currently sweeping the UK. A 
recent report has suggested that this strain has a significantly 
higher potential rate of transmission (R0) compared to pre-
vious variants [1,2]. Genomic analysis of the strain found 
substantial novel sequence variation caused by mutations, 
which may provide a biological reason for the observed 
increase in transmissibility. Initial assessments suggest the 
novel variants show an improved interaction with host cell 
receptors, such as ACE2 on epithelial cells [3]. This enables 
the virus to better establish and propagate infections, result-
ing in higher levels of virus in the host and increased rate of 
transmission [4,5].
A recent analysis of the transmission characteristics of the 
B.1.1.7 variant stratified by age suggests that its higher R0 
may be largely attributable to an increase in transmission to 
and among school-age children, whilst infection rates for 
older people appear to be less affected [2]. The successful 
emergence of such variants is most rapid with a higher R0. 
Such so-called “selective sweeps” are common in pathogen 
evolution. According to the Red Queen hypothesis [6], each 
increment in the fitness of the pathogen results in an equiva-
lent reduction in fitness of the host. If the R0 of the most 
virulent variant can be kept below one, it will not be able to 
further establish itself in the host population and replace the 
original strain. In simple terms, containing the outbreaks of 
highly virulent strains now won’t just save lives in the next 
months, but it will also save many lives in the years to come. 
Thus, a policy of minimizing the R0 by closing schools will 
help to contain the establishment of highly virulent strains. 
Employing vaccines is a more long-term strategy, but it will 
take several months to become an effective control measure.
Governments are negotiating a precarious balance 
between saving the economy and preventing COVID-19 
fatalities. However, the roll-out of economic stimulus 
packages and related activities in many countries appears 
to have fuelled the rate of person-to-person transmission. 
This created two distinct problems. Firstly, at the start of the 
winter, the population number of the virus continued from a 
much higher base than would otherwise have been the case. 
With an exponentially growing rate of the infection (R0 > 1), 
the time it takes to increase the number of infected hosts 
from N to 2 N people is the same, irrespective of N. In other 
words, if we had halved the number of infections, we would 
have had (approximately) half the number of cases now. 
Secondly, the probability that the pathogen evolves, and 
that the next infection is caused by the mutant strain of the 
virus, is equal to the mutation rate for each transmission (µ) 
[7]. By not absolutely minimizing the R0 when we had the 
chance, we extended the pathogen transmission chains, 
allowing it to mutate and evolve into more virulent variants. 
Put simply, more transmission leads to a higher chance of 
evolution of new strains, and it promotes selective sweeps 
and the establishment of such strains in the susceptible 
population. As such, continuing public health efforts to 
encourage vaccination as well as continued use of proper 
personal protective equipment (PPE), such as proper mask-
ing and maintaining safe social interactions, is of utmost 
importance.
COVID-19 vaccine deployment is now underway, but a 
threat to vaccine effectiveness comes from other emergent 
strains, both existing and yet to come. For example, another 
highly virulent SARS-CoV-2 variant has been identified in 
South Africa (SouthAfricaV501.V2 clade), which like B.1.1.7, 
appears to be transmitting more quickly than other strains. 
This lineage has rapidly become the dominant circulating 
strain, and it too is mutated in several areas of the viral spike 
protein [3] as are a group of Brazilian (B 1.1.28) variants now 
predominating in Amazonas state [8]. The fear is that varia-
tion generated by mutation could give rise to vaccine- 
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resistant strains in the long term. Such vaccine escaped 
mutants can potentially be favoured during protracted infec-
tions in patients with a weakened immune response and 
longer transmission chains. Such conditions increase the 
input of new mutations and the time for natural selection 
to act on this novel variation. Furthermore, rather than 
selecting for increased transmissibility, the next stage of 
virus evolution may involve adaptations that increase the 
duration that a host is contagious. After all, in directly 
transmitted parasites, R0 is the product of transmission effi-
ciency (β), the contact rate between susceptible hosts (c) and 
the duration (d) that an infected host is contagious [9]. A 
sufficient level of vaccination coverage will reduce the num-
ber of contacts between susceptible hosts, and hence, selec-
tion pressures for increased R0 are likely to involve 
adaptations that prolong the infection. Finally, strains evol-
ving independently in reservoir hosts (e.g. mink) have also 
been shown to contain viral spike protein mutations and be 
less readily neutralized by immune serum [10]. Continued 
virus evolution in reservoir animal host, followed by spillback 
events into susceptible human hosts, poses a significant long- 
term risk to public health. SARS-CoV-2 can infect a wide 
range of host species, including cats, dogs, mink, and other 
wild and domesticated species [11], and hence, the vaccina-
tion of domesticated animals might be required to halt 
further virus evolution and spillback events.
Whilst the vaccination campaigns against SARS-CoV- 
2/COVID-19 are being rolled out worldwide, new virus 
variants are likely to continue to evolve that have the 
potential to sweep through the human population. 
Higher transmission rates require a higher level of immu-
nity to bring R0 below one [12] and a more transmissible 
virus strain, such as the UK B.1.1.7 requires more people 
to be vaccinated in order to keep the virus and the disease 
it causes under control. Furthermore, higher transmission 
rates increase the evolutionary potential of the virus by 
increasing the input of new mutations, potentially result-
ing in even more virulent strains. Vaccination against a 
viral pathogen with such high prevalence globally is with-
out precedent and we, therefore, have found ourselves in 
unchartered waters. However, what we can be certain 
about is that, as long as vaccines remain effective, a higher 
uptake of the vaccines will: (1) reduce the number of 
COVID-19-related deaths, (2) stem the spread of the 
transmissible strain of the virus, and (3) reduce risk of 
the evolution of other, even more, virulent strains in the 
future. Furthermore, it is not unthinkable that vaccination 
of some domesticated animal species might also be neces-
sary to curb the spread of the infection.
Humanity is faced with a new reality. The faster we adapt, 
the better our long-term prospects. We must stop the evolu-
tion and spread of more virulent virus strains now. We, 
therefore, support public health policies with strict control 
measures in order to protect our public health system, our 
individual wellbeing, and our future.
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